Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

<p>Supplemental Figures 1 - 5</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Timothy P. DiPeri (16384177) (author)
Άλλοι συγγραφείς:	Kurt W. Evans (16384180) (author), Maria Gabriela Raso (15107821) (author), Ming Zhao (16384183) (author), Yasmeen Q. Rizvi (16384186) (author), Xiaofeng Zheng (16384189) (author), Bailiang Wang (16384192) (author), Bryce P. Kirby (16384195) (author), Kathleen Kong (16384198) (author), Michael Kahle (16384201) (author), Timothy A. Yap (15028749) (author), Ecaterina E. Dumbrava (16384204) (author), Jaffer A. Ajani (11016306) (author), Siqing Fu (15047712) (author), Khandan Keyomarsi (14958560) (author), Funda Meric-Bernstam (10258780) (author)
Έκδοση:	2025
Θέματα:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology DNA Damage and Repair Gastrointestinal Cancers Preclinical Models Translational Research
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
ανά: Sheheryar Kabraji (15050565)
Έκδοση: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
ανά: Jamunarani Veeraraghavan (16461809)
Έκδοση: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
ανά: Jamunarani Veeraraghavan (16461809)
Έκδοση: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
ανά: Jamunarani Veeraraghavan (16461809)
Έκδοση: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
ανά: Jamunarani Veeraraghavan (16461809)
Έκδοση: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
ανά: Jamunarani Veeraraghavan (16461809)
Έκδοση: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
ανά: Jamunarani Veeraraghavan (16461809)
Έκδοση: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
ανά: Jennifer L. Cotton (17315204)
Έκδοση: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
ανά: Javier Pascual (15018176)
Έκδοση: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
ανά: Milana A. Bergamino (15038015)
Έκδοση: (2025)

Supplementary Table S2 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
ανά: Gia-Buu Tran (16437051)
Έκδοση: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
ανά: Nigel Bundred (15046233)
Έκδοση: (2025)

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures
ανά: Vishwajith Sridharan (15047154)
Έκδοση: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
ανά: Alyssa C. Flint (16676029)
Έκδοση: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
ανά: Ulka N. Vaishampayan (15051039)
Έκδοση: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
ανά: Xufeng Lu (14960724)
Έκδοση: (2025)

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
ανά: Sebastian Johannes Schober (14971891)
Έκδοση: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
ανά: Carlotta Antoniotti (15352506)
Έκδοση: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
ανά: Santiago Duro-Sánchez (14959182)
Έκδοση: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
ανά: Alyssa C. Flint (16676029)
Έκδοση: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
ανά: Ulka N. Vaishampayan (15051039)
Έκδοση: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
ανά: Ulka N. Vaishampayan (15051039)
Έκδοση: (2025)

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
ανά: Jennifer L. Cotton (17315204)
Έκδοση: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
ανά: Jennifer L. Cotton (17315204)
Έκδοση: (2025)

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
ανά: Jennifer L. Cotton (17315204)
Έκδοση: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
ανά: Jennifer L. Cotton (17315204)
Έκδοση: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
ανά: Jennifer L. Cotton (17315204)
Έκδοση: (2025)

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
ανά: Jennifer L. Cotton (17315204)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_4hg70cgh4hhebu7uresgmla7rd